CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenue:
Genetic testing	$ 483,363	$ 677,168
Other	4,030	716
Total revenue	487,393	677,884
Cost of revenue	383,571	376,211
Gross profit	103,822	301,673
Operating expenses:
Research and development	160,380	446,274
Selling, general and administrative	1,002,172	1,136,649
Amortization of intangibles	28,863	28,863
Total operating expenses	1,191,415	1,611,786
Loss from operations	(1,087,593)	(1,310,113)
Other income (expense):
Interest income	739	743
Interest expense	(114,726)	(105,336)
Total other expense	(113,987)	(104,593)
Loss before income taxes	(1,201,580)	(1,414,706)
Benefit for income taxes	0	0
Net loss	$ (1,201,580)	$ (1,414,706)
Basic and diluted net loss per common share	$ (0.03)	$ (0.04)
Weighted average common shares outstanding, basic and diluted	36,775,504	36,748,063